Free Newsletter
CDC backs wide use of Merck's Zostavax
TODAY'S SPOTLIGHT... CDC backs wide use of Merck's Zostavax
The Centers for Disease Control and Prevention is giving a boost to Merck's Zostavax vaccine. The public health agency is recommending that all adults 60 years and older should get the herpes zoster shot to prevent shingles, a painful and sometimes long-lasting disease. Complications of shingles, such a pneumonia and blindness, are more common among older folks. The CDC's advice comes after a long peer-review process, and its official stamp could prompt more doctors to give the vaccine--and, importantly, more private insurance companies to cover it. Release | Report
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FiercePharma email newsletter for FREE!
Be the first to comment